Nasal Testosterone Gel Shown to Normalize Androgen Levels, Improve Erectile Function & Mood in Hypogonadal Men – UroToday
Posted: June 21, 2017 at 9:46 am
Two research reports from the 2017 American Urological Associations annual meeting, May 12-16 in Boston, demonstrated that treatment with the novel 4.5% nasal testosterone gel, (marketed as NatestoR), restored total serum testosterone to normal levels while preserving normal concentrations of pituitary gonadotropins in men with hypogonadism1, and led to clinical improvements in both erectile function and mood. 2
In an open-label, dose-ranging study, reported by William Conners, MD, from Harvard Medical School and Mens Health Boston, hypogonadal subjects were randomized to self-administer NatestoR either twice daily (BID) (n=122) or 3 times daily (TID) (n=151), for a total daily dose of 22.0 mg or 33.0 mg, respectively, over 90 days. Titration was based on mens blood levels, aiming to achieve the eugonadal range of 300-1050 ng/dL. Serum samples were obtained from subjects at baseline and after 90 days. 1
The treatment resulted in an increase in total serum testosterone from a mean Cavg 200.8 ng/dL at baseline to a mean Cmax 818.49 ng/dL at about 40 minutes.
After 90 days, 90% of men in the TID group, and 71% of men in the BID group reached normal testosterone levels, and a mean total testosterone Cavg 421 ng/dL and 375 ng/dL, respectively.1
Baseline follicle-stimulating hormone (FSH) in the BID group was 8.49 IU/L: the mean at day 90 FSH was 5.99 IU/L. Baseline FSH in the TID daily group was 6.42 IU/L. The mean at day 90 was 3.12 IU/L. Baseline luteinizing hormone (LH) in the BID group was 5.42 IU/L. The mean at day 90 was 3.56 IL/L. The baseline TID group was 5.25 IU/L. The mean at day 90 was 2.20 IU/L. 1
The authors concluded that treatment with the 4.5% nasal testosterone gel, NatestoR, restored serum total testosterone to normal levels. Although FSH and LH levels were reduced, they noted that mean levels remained well within the normal range, in a finding that contrasts with other therapies for hypogonadism, injections in particular. 1
In another evaluation of the efficacy and safety of the 4.5% nasal gel, NatestoR, authors led by Dr. Larry Lipshultz, from Baylor University College of Medicine, reported the extent of clinical improvements in erectile function and mood, in a 90-day, randomized, open-label, dose-ranging study in hypogonadal men, with sequential safety extensions to one year. 2
The investigators evaluated erectile function and mood at baseline (day 0), and at 30-day intervals throughout the 90-day treatment period using the International Index of Erectile Function (IIEF) and the Positive and Negative Affect Schedule (PANAS).
Results demonstrated that treatment with NatestoR resulted in statistically significant improvements in each of the 5 domains of erectile function (F(3,8,13) =83.96, p<.001). Most of the benefit was evident by day 30 (t= -9.8714, df=288, p- value <.001), with smaller increases until completion of the study (Figure 1)
NatestoR also produced clinically and statistically significant improvements in mood, as assessed by PANAS, by day 30. Continued improvements in mood were seen through the studys completion (Figure 2).
Gerwin Westfield, PhD, Medical Affairs Manager with Aytu BioScience, spoke with UroToday about these results, which are unique when compared with effects of other forms of testosterone therapy, especially by a notable lack of suppression of pituitary gonadotropins LH and FSH.
Men who were treated with NatestoR nasal testosterone gel had significant improvements in mood as early as 30 days, and continued improvement all the way out to Day 90representing both significant improvements in the positive mood attributes and significant improvement in negative mood attributes. This finding was quantified by the self-reporting instrument PANAS, (Positive and Negative Affect Schedule).
Moreover, said Dr. Westfield, treatment with NatestoR showed statistically significant improvement in all five domains of erectile function as early as Day 30, and the improvement continued to Day 90.
References: 1. Conners W, Morgentaler A, Guidry M, Westfield G, Bryson N, Goldstein I. Preservation of normal concentrations of pituitary gonadotropins despite achievement of normal serum testosterone levels in hypogonadal men treated with a 4.5% nasal testosterone gel. American Urological Association. May 12-16, 2017. Poster MP89-06. 2. Lipshultz LI, Westfield G, Guidry M, et al. Clinical improvements in erectile function and mood in hypogonadal men treated with 4.5% nasal testosterone gel. American Urological Association. May 12-16, 2017. Poster PD69-06.
- Testosterone Treatment and Fractures in Men with Hypogonadism | NEJM - nejm.org - January 20th, 2024
- Understanding Hypogonadism, Testosterone Replacement Therapy, and Prostate Cancer Risk - Medriva - January 11th, 2024
- Male hypogonadism - Patient Information - January 3rd, 2024
- Testosterone replacement therapy may not increase risk of prostate cancer among men with hypogonadism - Medical Dialogues - January 3rd, 2024
- Male Hypogonadism Market Expected to Reach $5.1 Billion by 2030 | Current Trends and Industry Analysis - EIN News - December 16th, 2023
- Hypogonadism: What Is It, Causes, Signs and Symptoms, and More - Osmosis - November 2nd, 2023
- Hypogonadism - StatPearls - NCBI Bookshelf - February 10th, 2023
- Male hypogonadism: Symptoms and treatment - PMC - PubMed Central (PMC) - February 10th, 2023
- The 'male menopause' - NHS - November 26th, 2022
- Diagnosis of Hypogonadism: Clinical Assessments and Laboratory Tests - November 1st, 2022
- Approach to the Patient With Hypogonadotropic Hypogonadism - November 1st, 2022
- Clomiphene citrate for men with hypogonadism: a systematic ... - PubMed - September 21st, 2022
- Hypogonadism in females | DermNet - September 21st, 2022
- Clomiphene citrate effects on testosterone/estrogen ratio in male ... - September 21st, 2022
- Male Hypogonadism Market Size to Grow by USD 684.95 Mn, AbbVie Inc. and Bayer AG Among Key Vendors - Technavio - Longview News-Journal - September 21st, 2022
- Male sexual health and reproductive medicine: All that glitters is not gold - Urology Times - September 21st, 2022
- The Reproductive Outcome of Women with HH in IVF - Physician's Weekly - August 20th, 2022
- Men's Health Market is Slated to Witness Tremendous Growth in Coming Years | Latest Report by IBI - Digital Journal - August 20th, 2022
- Why Can Some Medicines Increase The Risk Of Osteoporosis? - Nation World News - August 20th, 2022
- What is Erectile dysfunction (aka ED)? : Buy Kamagra to treat the ED - My MMA News.com - August 20th, 2022
- Sure Signs Your Endocrine System Isn't as Strong as it Should Be Eat This Not That - Eat This, Not That - August 11th, 2022
- What has the NFL said about Packers QB Rodgers consuming ayahuasca? - AS USA - August 11th, 2022
- Male hypogonadism: Symptoms, causes, and treatment - Medical News Today - July 8th, 2022
- Hypogonadism in Men | Endocrine Society - July 8th, 2022
- Olfactory Radioanatomical Findings in Patients With Cardiac Arrhythmias, COVID-19, and Healthy Controls - Cureus - July 8th, 2022
- Global Hormone Replacement Therapy Market Is Projected To Thriving At A CAGR of 1.51% During 2022-2028 | 120 Report Pages - Digital Journal - July 8th, 2022
- Testosterone May Aid Memory in Men With Uncontrolled Diabetes - Everyday Health - June 28th, 2022
- Cardiovascular Effects of Androgen Deprivation Therapy in Prostate Cancer Patients: A Systematic Review - Cureus - June 28th, 2022
- EffRx Pharmaceuticals Signs Exclusive License Agreement With Diurnal for the Registration and Commercialization of Efmody in Switzerland - Business... - April 28th, 2022
- Tucker Carlson hawks testicle tanning to boost testosterone. Experts say it may do the opposite - Salon - April 28th, 2022
- A practical guide to male hypogonadism in the primary care ... - January 1st, 2022
- Waist Circumference Is More Closely Associated with Hypogonadism than Is Hyperglycemia, Independent of BMI in Middle-Aged Men - DocWire News - January 1st, 2022
- Andrological aspects of new coronavirus infection Covid-19 - DocWire News - January 1st, 2022
- Reviewing the Top 5 Best Male Enhancement Pills in 2022 to Buy - The Daily World - January 1st, 2022
- Low Sex Drive (Hypogonadism): Symptoms, Treatment - December 22nd, 2021
- Androgen Deprivation Therapy and the Risk for Inguinal Hernia: An Observational Nested Case Control Study - DocWire News - December 22nd, 2021
- 5 Best Testosterone Boosters to Increase Testosterone Levels in 2022 - Us Weekly - December 22nd, 2021
- Male hypogonadism | You and Your Hormones from the Society ... - November 21st, 2021
- Low testosterone predicts hypoxemic respiratory insufficiency and mortality in patients with COVID-19 disease: another piece in the COVID puzzle -... - November 21st, 2021
- CLARUS THERAPEUTICS HOLDINGS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q) -... - November 21st, 2021
- Bio-Identical Hormone Replacement Therapy Market to Rise Due to the Increasing Applications and Wider Reach, Players Pfizer Bayer. Energy Siren -... - November 21st, 2021
- Hormone Replacement Therapy Market Rise in Sustainability Around The World 2021 2030 - Taiwan News - October 5th, 2021
- 6 Things To Look for In a Good Testosterone Booster Supplement - The Portugal News - October 5th, 2021
- Androgen Deprivation Therapy, Hypogonadism and Cardiovascular Toxicity in Men with Advanced Prostate Cancer - DocWire News - October 5th, 2021
- [PDF] Hormone Replacement Therapy Market to Reflect Steady Growth and Future Scope UNLV The Rebel Yell - UNLV The Rebel Yell - August 30th, 2021
- Top 6 Benefits of Testosterone Therapy Times Square Chronicles - Times Square Chronicles - August 3rd, 2021
- Hormone Replacement Therapy Market by 2027 Worldwide Growth Opportunities Recent Trends Forecast by Types and Application to 2027 The Manomet Current... - August 3rd, 2021
- 9 Ways to Increase Testosterone Naturally in 2021 - Men's Journal - August 3rd, 2021
- Testosterone Therapy for Hypogonadism Guideline Resources ... - May 26th, 2021
- Clarus Therapeutics And HavaH Therapeutics Announce Licensing Agreement For Product To Treat Androgen-Dependent Inflammatory Breast Disease And... - May 26th, 2021
- Trending Report of Male Hypogonadism Market Drivers, Strategies, Applications and Competitive Landscape 2026 Brockville Observer - Brockville... - May 26th, 2021
- Male menopause: Here's everything you need to know about andropause - Pulse Ghana - May 26th, 2021
- Blue Water Acquisition : Clarus Therapeutics And HavaH Therapeutics Announce Licensing Agreement For Product To Treat Androgen-Dependent Inflammatory... - May 26th, 2021
- Hormone Replacement Therapy Market Size to Surpass US$ 36.54 Billion by 2027 with the CAGR of 8.20% The Manomet Current - The Manomet Current - May 26th, 2021
- The many effects of reproductive hormones on the brain - ESHRE - May 26th, 2021
- Hormone Replacement Therapy (HRT) Market to Eyewitness Stunning Growth by 2027 Covid-19 Analysis The Shotcaller - The Shotcaller - May 26th, 2021
- The Male Hypogonadism Market To Witness Steadfast Growth In The Next 10 Years The Courier - The Courier - May 14th, 2021
- The Male Hypogonadism Market To Ride On Innovations KSU | The Sentinel Newspaper - KSU | The Sentinel Newspaper - May 14th, 2021
- Hormone Replacement Therapy Market Global Industry Scope and Growth Analysis Report 2021: Opportunity Assessment, Business Boosting Strategies, and... - May 14th, 2021
- Global Hormone Replacement Therapy (HRT) Industry Market Report 2020, Forecast Till 2027 By Type, End-use, Geography and Player The Courier - The... - May 14th, 2021
- Immunosenescence Profile and Expression of the Aging Biomarker (p16INK4a) in Testicular Cancer Survivors Tr... - UroToday - February 11th, 2021
- Europe to hold The major Piece of Cake in the Anabolic Steroids Market between 2020 and 2030 Jumbo News - Jumbo News - February 11th, 2021
- The Male Hypogonadism Market to witness a splendid CAGR in the next decade Murphy's Hockey Law - Murphy's Hockey Law - February 3rd, 2021
- Testosterone for Managing Treatment-related Fatigue in Patients With Metastatic Renal Cell Carcinoma: A Pha... - UroToday - February 3rd, 2021
- Marius Pharmaceuticals Announces Co-CEOs Himanshu H. Shah and Shalin Shah to Drive Growth ahead of Anticipated FDA Action of its Lead Asset, KYZATREX... - January 29th, 2021
- Male Hormone Replacement Therapy And The Side Effects - Nerd's Magazine - January 29th, 2021
- New York Medical and Life Sciences: Year in Review 2020 - JD Supra - January 29th, 2021
- Male menopause: symptoms, diagnosis and treatment - Netdoctor - January 29th, 2021
- Freeman: 'Pressure to Succeed' Led to Testosterone Order - Medscape - January 27th, 2021
- Hormone Replacement Therapy Market Growth Analysis,Size,Insight,Share And Outlook By 2027 Pfizer, AbbVie, Novo Nordisk NeighborWebSJ - NeighborWebSJ - January 27th, 2021
- Male Hypogonadism Therapy Market to Witness Massive Growth During 2021-2027 | Eli Lilly, Pfizer, AbbVie, Novo Nordisk, Merck KGaA, Mylan, Bayer, Teva,... - January 25th, 2021
- Male Hypogonadism Therapy Market and Ecosystem by Production, Prospects, Consumption, Cost Structure, Competitive Landscape - Jumbo News - January 25th, 2021
- What is Harvey Prices disability Prader-Willi Syndrome? - The Sun - January 25th, 2021
- The Male Hypogonadism Market To Witness An Escalating CAGR Of 3.7% - NeighborWebSJ - January 19th, 2021
- Androgen Replacement Therapy Market to Witness Robust Expansion throughout the Forecast Period 2017-2026 | AbbVie, Inc., Allergan Plc, Bayer AG, Endo... - January 19th, 2021
- Global COVID-19 Diagnostics Market Size Worth USD 11.40 Billion at 7.9% CAGR; Pharmaceutical Giants Such as Abbott and Roche to Pump More Funds for... - January 19th, 2021
- Marius Pharmaceuticals Submits New Drug Application to US FDA for Next-Generation Oral Testosterone Replacement Therapy in Male Patients With... - January 12th, 2021
- Testosterone Replacement Therapy Market (2020 2027) Explosive Factors of Revenue by Key Manufacturer, Share, Future Trends, COVID-19 Market Scenario,... - January 9th, 2021
- The Anabolic Steroids Market to sharpen in the next decade - The Monitor - January 9th, 2021
- Brief Report Treatment of infertility and menopause in a patient with multiple sclerosis affecting the pituitary stalk: a case report - DocWire News - December 24th, 2020